CBG Study Guide 2026: How to Pass on Your First Attempt

What You Are Actually Preparing For

Clinical Biochemical Genetics (CBG) is the board certification pathway administered by the American Board of Medical Genetics and Genomics (ABMGG) for professionals who interpret and direct laboratory testing for inherited metabolic disease. If you are searching for a study plan, you are probably already comfortable with the idea that this is a specialist exam rather than a general genetics test. It asks you to connect a biochemical finding, a clinical presentation, and a laboratory method, and to reason across all three.

If you are still orienting yourself on the credential itself, the explainers on what CBG certification is and what CBG stands for cover the basics. This guide assumes you have decided to sit for the exam and want a blueprint-driven plan to pass the first time.

Reading the Blueprint Weights Like a Strategist

The blueprint lists fifteen content categories, each with an approximate percentage. Those percentages, as published, are 15, 12, 7, 10, 13, 12, 7, 3, 3, 3, 1, 2, 3, 8, and 3. They add up to 102%, a discrepancy that exists in the source itself. Do not try to normalize them or build a mathematically precise time budget around them. Treat them as relative signals of emphasis.

The practical takeaway is that the four largest domains (amino acids, lipids, organic acids, lysosomes) together account for roughly half of the published weight. A candidate who is rock solid there and merely competent elsewhere is in a much stronger position than one who spreads effort evenly. For a category-by-category walkthrough, see the complete guide to all 15 CBG content areas.

The Heavy Hitters: Amino Acids, Lipids, Organic Acids, and Lysosomes

Amino acids (about 15%)

This is the single biggest domain and the natural foundation for everything else. The blueprint names PKU and hyperphenylalaninemia, tyrosinemias, glycine encephalopathy/hyperglycinemia, MSUD and disorders of branched-chain amino acids, homocystinuria and disorders of sulfur amino acids and re-methylation, urea cycle defects, and an Other/Serine group.

Urea cycle defects deserve extra time because the exam can test the same pathway from several angles: the metabolite pattern, the acute emergency, and the long-term dietary approach.

Lipids (about 13%)

The lipids domain covers fatty acid oxidation disorders, including short-chain, medium-chain, long-chain, and multiple acyl-CoA dehydrogenase deficiency (GA2), plus hyperlipidemias (including Tangier disease) and disorders of cholesterol metabolism such as Smith-Lemli-Opitz, Niemann-Pick C, and bile acid disorders.

Fatty acid oxidation is the part most candidates find manageable because the acylcarnitine logic is systematic: each chain-length defect produces a characteristic accumulation pattern. The cholesterol side is where people slip. Know which sterol intermediate accumulates in Smith-Lemli-Opitz, and keep Niemann-Pick C distinct from the Niemann-Pick A and B forms you will meet in the lysosomal domain.

Organic acids (about 12%)

Here the blueprint specifies methylmalonic acidemia (excluding cobalamin defects) and propionic acidemia; 3-MCC deficiency and other C5OH-related disorders; IVA and other C5-related disorders; glutaric acidemia type I; disorders of ketone body metabolism (HMG-CoA lyase, SCOT); and an Other group including glutathione synthetase deficiency, ECHS1, and 3-methylglutaconic aciduria non-type 1.

Note the explicit exclusion of cobalamin defects from the methylmalonic acidemia line. Those belong in the Cofactors domain, and keeping the boundary clear helps you answer questions that deliberately blur it.

Lysosomes (about 12%)

The lysosomal domain spans the mucopolysaccharidoses (Types I, II, III, IV, VI, and VII), the sphingolipidoses (Gaucher, Fabry, the GM2 gangliosidoses including Tay-Sachs and Sandhoff, Krabbe, Niemann-Pick A and B, GM1 gangliosidosis), multiple enzyme deficiencies (mucolipidoses ML-II and ML-III, multiple sulfatase deficiency), and an Other group with Pompe, cystinosis, and NCL.

Remember that GSD II is excluded from the carbohydrate glycogenoses line precisely because it lives under Lysosomes. That kind of cross-domain routing is a recurring theme in the blueprint.

Mid-Weight Domains That Quietly Decide Your Result

Carbohydrates (about 10%)

The blueprint covers glycogenoses (except GSD II), disorders of glycolysis, gluconeogenesis (including fructose-1,6-bisphosphatase deficiency), galactose metabolism, fructose metabolism, congenital disorders of glycosylation, and an Other group including the pentose phosphate pathway. Galactosemia and fructose disorders are classic exam territory because the clinical story (feeding history, hypoglycemia, liver involvement) points directly to the pathway. Congenital disorders of glycosylation reward knowing the transferrin isoform concept at the level of how the testing is interpreted.

Cofactors (about 7%) and Mitochondria (about 7%)

Cofactor disorders (cobalamin, biotin, molybdenum, folate, pyridoxine, biopterin, and others including riboflavin, niacin, and thiamine) are high-yield for their size because treatment is often cofactor supplementation, and the exam likes to test whether you recognize a treatable condition. Mitochondrial disease is broader in scope: laboratory findings in myopathies, Leigh syndrome, adult presentations, electron transport chain function and assembly, mtDNA mutation and maintenance disorders, depletion syndromes, and MELAS. Here the challenge is less about single pathways and more about reasoning when lab findings are nonspecific.

Small Domains: Cheap Points If You Stay Disciplined

Eight categories carry roughly 3% or less each, and several are only a few questions' worth of exposure. They are small, but they are also the easiest places to pick up points with a focused, short review, because the scope is narrow.

• Peroxisomes (3%): biogenesis disorders such as Zellweger syndrome, single-enzyme disorders including X-linked adrenoleukodystrophy, and Refsum (infantile). Anchor on very-long-chain fatty acids.
• Purines and pyrimidines (3%): Lesch-Nyhan disease, adenosine deaminase deficiency, and pyrimidine disorders such as UMP synthase deficiency.
• Transport (3%): dibasic aminoaciduria including cystinuria and lysinuric protein intolerance, other amino acid transport disorders, glucose, and carnitine.
• Metals (3%): copper (Wilson and Menkes diseases), iron, zinc, and others. Know the copper and ceruloplasmin pattern cold.
• Neurotransmitters (2%): SSADH deficiency, disorders of dopamine synthesis, and GABA metabolism.
• Creatine (1%): a single-line category; a short review of the creatine synthesis and transport defects is enough.
• Other disease category (3%): a catch-all, so broad familiarity with unusual presentations serves you better than deep drilling.

Because these domains are small, resist the urge to over-invest. A single focused session per category is a reasonable allocation for most candidates.

The Laboratory Domain: Where Clinicians Lose Points

At about 8%, the Laboratory domain is larger than any of the small disease categories and larger than cofactors or mitochondria individually. It covers QA/QC, artifact, techniques, and regulations. Candidates trained primarily on the clinical side often under-prepare here, while laboratory-trained candidates sometimes under-prepare on the clinical domains. Check yourself honestly against your own background.

Artifacts deserve particular attention because they generate some of the most instructive interpretive questions: a result that looks like a metabolic disease but is explained by something outside the patient's biochemistry. Practicing that skepticism is directly examinable.

Sequencing Your Study Across the Prep Window

Because the exam is offered only in odd years for the biochemical specialties, with the next one identified as August 2027, you have a long runway. Use it to build in layers rather than cramming. The timeline below shows one way to order the domains, based on dependency and weight rather than on a generic template.

The key principle is to finish the small domains and Laboratory before your final integration phase, so that late-stage practice is genuinely mixed rather than still introducing new material.

Practice Questions and Pattern Recall

The exam tests whether you can reason from data to diagnosis, so your practice should mirror that. Questions in this field typically present a clinical vignette with laboratory values and ask for the most likely diagnosis, the next confirmatory test, or the right management step. Because the blueprint does not publish the number of questions or the time limit in the source material available for this guide, do not build your pacing around any specific figure you find elsewhere; confirm current exam format details directly with ABMGG.

What you can control is the quality of your recall. A few habits tied directly to this exam:

• Build disorder cards around the marker, not the name. Start from "elevated C5OH acylcarnitine" and work toward the differential, because that is how the data arrive in a real case.
• Practice cross-domain traps. Cobalamin defects versus classic methylmalonic acidemia, GSD II versus other glycogenoses, and Niemann-Pick C versus Niemann-Pick A/B are exactly the splits a good question writer exploits.
• Rehearse the emergency logic. For urea cycle defects, organic acidemias, and MSUD, know what you would send, what you would start, and what you would avoid in an acute decompensation.

To check where your recall is thin, work through scenario-based questions on the CBG practice test site, then return to the blueprint to map every miss to its domain. Tracking misses by domain tells you far more than an overall score does. Our one-page CBG cheat sheet is a handy complement for consolidating the facts you keep forgetting.

Timing, Eligibility, and Logistics

Two logistical facts shape your plan. First, ABMGG has approved a transition to an annual certifying examination schedule, but the biochemical specialties are still tied to odd-numbered years, and the next exam is identified as August 2027. Check ABMGG announcements directly for the final scheduling details, because exam windows and deadlines can change. For a deeper treatment, see our guide to CBG exam dates, windows, and deadlines.

Second, the fee, the passing score, and the exact question count and timer were not established from the official source content used for this guide, so they are not stated here. Rather than rely on figures from unofficial sources, confirm them at abmgg.org. You can also read our breakdowns of CBG certification cost and the CBG passing score for how to approach those questions, and review CBG eligibility and prerequisites before you commit to a date.

Why the Effort Pays Off Professionally

Board certification in this specialty positions you for roles that interpret and oversee metabolic testing: clinical biochemical genetics laboratories, hospital and academic medical centers with biochemical genetics services, and reference laboratories that run newborn screening confirmation and metabolic panels. The credential signals that you can responsibly sign out complex results, which is exactly what these employers need. If you are weighing the decision, our analyses of whether the CBG certification is worth it and the CBG salary landscape look at the career case in more detail, and our overview of CBG jobs shows where certified professionals tend to work.

Frequently Asked Questions

The most reliable path to a first-attempt pass is to let the blueprint drive your priorities: master the four heavy domains, treat Laboratory as a real section, sweep the small categories efficiently, and practice recognizing disorders from mixed data. For the broader picture, return to our main CBG study guide hub, and keep testing yourself against realistic questions as the exam approaches.